Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 403 publications

Medicinal chemistry perspective on quinazoline derivatives: Sustainable synthetic routes, anticancer evaluation, and SAR analysis.

Medicinal chemistry perspective on quinazoline derivatives: Sustainable synthetic routes, anticancer evaluation, and SAR analysis.

Journal: European journal of medicinal chemistry
Published: October 12, 2025

Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC).

Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC).

Journal: Journal of clinical medicine
Published: September 07, 2025

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 20, 2025

Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis.

Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis.

Journal: BMC cancer
Published: July 10, 2025

Sequential tyrosine kinase inhibitor therapy for EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient: a 24-month case report.

Sequential tyrosine kinase inhibitor therapy for EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient: a 24-month case report.

Journal: Frontiers in medicine
Published: July 10, 2025

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.

Journal: Molecular oncology
Published: July 04, 2025

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study.

Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study.

Journal: Frontiers in pharmacology
Published: June 24, 2025

Inhibition of primary ciliogenesis enhances efficacy of EGFR‑TKIs against non‑small cell lung cancer cells.

Inhibition of primary ciliogenesis enhances efficacy of EGFR‑TKIs against non‑small cell lung cancer cells.

Journal: Oncology reports
Published: June 23, 2025

Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer.

Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer.

Journal: Cureus
Published: June 11, 2025

Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation.

Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation.

Journal: Expert review of pharmacoeconomics & outcomes research
Published: June 09, 2025

Recent Advances in the Use of Ganoderma lucidum and Coriolus versicolor Mushrooms to Enhance the Anticancer Efficacy of EGFR-Targeted Drugs in Lung Cancer.

Recent Advances in the Use of Ganoderma lucidum and Coriolus versicolor Mushrooms to Enhance the Anticancer Efficacy of EGFR-Targeted Drugs in Lung Cancer.

Journal: Pharmaceutics
Published: May 31, 2025

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.

Journal: Pharmacological research
Published: May 27, 2025
Showing 1-12 of 403

Last Updated: 02/24/2026